Health

“We studied in a cohort for six months where Covaxin induced good memory response. So we are confident that till six months of full immunisation, no booster dose is required. A follow up of this cohort thereafter, will help us to understand if we really need booster shots or not,” said Dr Nimesh Gupta, corresponding author of the study at NII. “The best protection was found against alpha then delta and the least was against beta variants,” he added.

Union Minister of State (Independent Charge) Science & Technology; Minister of State (Independent Charge) Earth Sciences; MoS PMO, Personnel, Public Grievances, Pensions, Atomic Energy and Space, Dr Jitendra Singh today launched first of its kind, latest, world’s most sophisticated MRI facility at the National Brain Research Centre (NBRC), Manesar Haryana, India’s premier institute dedicated to Neuroscience Research and Education.

As of Tuesday night, of the 755.4 million people who have received at least one shot of the Covid-19 vaccine in India, 380.7 million people are fully vaccinated (have received both shots) and another 374.7 million have received only one shot, according to data from the CoWIN dashboard. When seen alongside India’s estimated population of 940 million adults, this means that 40.3% of the country’s adults have been fully vaccinated while another 40.2% have been given a single jab so far.

NEW DELHI: Indicating “a low-level of Covid in India”, the Centers for Disease Control and Prevention (CDC) issued a Level-1 (lowest threat level) for the country, the US state department said.

The formulation has the medicinal herb Bergenia ciliata, which can help ease pain in rheumatoid arthritis

A day after World Health Organisation(WHO) granted emergency use approval for Bharat Biotech’s COVID-19 vaccine Covaxin, an official of the US Centers for Disease Control and Prevention (CDC) has informed that all travellers fully vaccinated against COVID-19 with Covaxin have been given the green light to enter the United States from November 8.

Covaxin was also reviewed by WHO’s Strategic Advisory Group of Experts on Immunization (SAGE), and recommended its use in two doses, with a dose interval of four weeks, in all age groups 18 and above.